In the second week after laboratory-confirmed COVID-19, the levels of serum ACE2 and AXL in the severe group (n=93) were significantly higher than that in the non-severe group (n=67), while SARS-COV-2 IgG was significantly lower (Figures 2E-G). This evidence concerns the gene ACE2 and COVID-19.